[18F]FDOPA PET/CT is superior to [68Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytoma

• Published in: EJNMMI research Vol. 13; no. 1; p. 108
• Main Authors: Iversen, Peter, Kramer, Stine, Ebbehoj, Andreas, Søndergaard, Esben, Stochholm, Kirstine, Poulsen, Per Løgstrup, Hjorthaug, Karin
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 18.12.2023; Springer Nature B.V; SpringerOpen
• Subjects: Accuracy; Cardiac Imaging; Computed tomography; Diagnosis; Diagnostic systems; DOTATOC; Drug dosages; Endocrinology; FDOPA; Fluorine isotopes; Hospitals; Imaging; Internal medicine; Lesions; Localization; Medical imaging; Medicine; Medicine & Public Health; Metastasis; Nuclear Medicine; Oncology; Original Research; Orthopedics; Paraganglioma; Patients; PET; Pheochromocytoma; Positron emission; PPGL; Radiology; Sensitivity analysis; Tumors; PPGL; PCC; Pheochromocytoma; PC; PGL; DOTATOC; FDOPA; Paraganglioma; PET
• ISSN: 2191-219X; 2191-219X
• DOI: 10.1186/s13550-023-01056-4

Background Both [ 18 F]FDOPA (FDOPA) and [ 68 Ga]DOTATOC PET/CT (DOTATOC) are widely used for detection of pheochromocytomas/paraganglioma (PPGL). However, direct comparisons of the performance of the two tracers are only available in small series. We conducted a retrospective comparative analysis of FDOPA and DOTATOC to assess their sensitivity and accuracy in detecting PPGL when administered based on suspicion of PPGL. We consecutively included patients referred on suspicion of PPGL or PPGL recurrence who were scanned with both FDOPA and DOTATOC. Both scans were reviewed retrospectively by two experienced observers, who were blinded to the final diagnosis. The assessment was made both visually and quantitatively. The final diagnosis was primarily based on pathology. Results In total, 113 patients were included (97 suspected of primary PPGL and 16 suspected of recurrence). Of the 97 patients, 51 had pheochromocytomas (PCC) (in total 55 lesions) and 6 had paragangliomas (PGL) (in total 7 lesions). FDOPA detected and correctly localized all 55 PCC, while DOTATOC only detected 25 (sensitivity 100% vs. 49%, p  < 0.0001; specificity 95% vs. 98%, p  = 1.00). The negative predictive value (100% vs. 63%, p  < 0.001) and diagnostic accuracy (98% vs. 70%, p  < 0.01) were higher for FDOPA compared to DOTATOC. FDOPA identified 6 of 6 patients with hormone producing PGL, of which one was negative on DOTATOC. Diagnostic performances of FDOPA and DOTATOC were similar in the 16 patients with previous PPGL suspected of recurrence. Conclusions FDOPA is superior to DOTATOC for localization of PCC. In contrast to DOTATOC, FDOPA also identified all PGL but with a limited number of patient cases.